Lupin charts biosimilar growth strategy, eyes capacity expansion

Lupin Pharmaceuticals has outlined an ambitious growth strategy centred on biosimilar products, with plans to substantially increase production capacity to meet anticipated demand. The pharmaceutical company's medium-term outlook reflects growing confidence in the biosimilar segment, which has emerged as a key revenue driver for Indian drugmakers competing in global markets.

As part of its expansion roadmap, Lupin is preparing to initiate a funding process for Kaveri Therapeutics, its dedicated oncology subsidiary. The move signals the company's intent to bolster its specialised cancer treatment portfolio, with Kaveri currently housing two focused oncology programmes designed to address unmet therapeutic needs.

The funding initiative for Kaveri Therapeutics is expected to provide the subsidiary with necessary capital to accelerate its clinical development timelines and expand its research capabilities. This separation of oncology operations into a dedicated vertical allows Lupin to pursue focused growth strategies within the specialised therapeutics domain while maintaining its core pharmaceutical operations.

The company's emphasis on biosimilars aligns with broader industry trends, as Indian manufacturers increasingly capture market share in biosimilar segments globally, where patent expirations of major biologic drugs have created substantial commercial opportunities. Lupin's capacity expansion plans underscore the sector's growth potential in coming years.